Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Summit Therapeutics drops 11.2% after FDA rejects ivonescimab application

Summit Therapeutics drops 11.2% after FDA rejects ivonescimab application

智通财经智通财经2026/11/16 14:51
Show original
Affected by the FDA's rejection of the approval application for the lung cancer drug ivonescimab, $Summit Therapeutics (SMMT.US)$ fell by 11.2% during trading. The highest turnover put option recorded a price change of +26%, with a trading volume of 73 contracts. For details, please refer to the option rankings on the options page. Option prices are highly volatile, so please be aware of the risks. Click to view the SMMT option chain.
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!